Accordingly, the present study was designed to develop an ELISA in‐house to explore how plasma anti‐p16 IgG levels were changed in patients with NSCLC and whether anti‐p16 IgG could be used as diagnostic biomarkers for screening of NSCLC. The gene discussed is CDKN2A; the disease is non-small cell lung carcinoma.